- ARIAD Pharmaceuticals (NASDAQ:ARIA) Q3 results: Revenues: $46M (+58.1%); Operating Loss: ($25M) (+55.7%); Net Loss: ($27.8M) (+49.9%); Loss Per Share: ($0.14) (+51.7%); Non-GAAP Loss Per Share: ($0.12) (+50.0%); Quick Assets: $314.7M (+29.9%); CF Ops: ($121.4M) (-0.6%).
- 2016 Guidance: Global Iclusig Net Product and Royalty Revenue: $170M - 180M; R&D Expense: $175M - 180M; SG&A Expense: $120M - 125M; cash, cash equivalents and marketable securities: $280M - 290M.